| Literature DB >> 35408789 |
Nicolas Germain1,2, Melanie Dhayer1, Salim Dekiouk1, Philippe Marchetti1,2.
Abstract
Tumor cells evolve in a complex and heterogeneous environment composed of different cell types and an extracellular matrix. Current 2D culture methods are very limited in their ability to mimic the cancer cell environment. In recent years, various 3D models of cancer cells have been developed, notably in the form of spheroids/organoids, using scaffold or cancer-on-chip devices. However, these models have the disadvantage of not being able to precisely control the organization of multiple cell types in complex architecture and are sometimes not very reproducible in their production, and this is especially true for spheroids. Three-dimensional bioprinting can produce complex, multi-cellular, and reproducible constructs in which the matrix composition and rigidity can be adapted locally or globally to the tumor model studied. For these reasons, 3D bioprinting seems to be the technique of choice to mimic the tumor microenvironment in vivo as closely as possible. In this review, we discuss different 3D-bioprinting technologies, including bioinks and crosslinkers that can be used for in vitro cancer models and the techniques used to study cells grown in hydrogels; finally, we provide some applications of bioprinted cancer models.Entities:
Keywords: 3D bioprinting; 3D printing; bioink; cancer; cell biology
Mesh:
Substances:
Year: 2022 PMID: 35408789 PMCID: PMC8998835 DOI: 10.3390/ijms23073432
Source DB: PubMed Journal: Int J Mol Sci ISSN: 1422-0067 Impact factor: 5.923
Most commonly used bioprinting technologies.
| Type of Technology | Example of Printing Method | Advantages | Disadvantages | Cell Density | Average Cell Viability | Crosslinking | References |
|---|---|---|---|---|---|---|---|
| Droplet-based | Laser | Very high accuracy and resolution | Only low-viscosity bioinks | Low (less than 10 million per mL) | High | Depends on biomaterial used | [ |
| Inkjet | High accuracy | [ | |||||
| Filament-based | Worm drive | Large panel of bioinks available | Higher shear stress and lower cell viability than other bioprinting technologies | High (more than 10 million per mL) | Medium/high depending on nozzle and pressure | Depends on biomaterial used | [ |
| Plane-based/Volumetric | DLP/SLA | Fast for large and complex 3D models | Few bioinks available | High (more than 10 million per mL) | High | Photocurable by DLP/SLA technology | [ |
Figure 1Examples of bioprinting and crosslinking technologies.
Examples of bioinks and their applications in cancer research.
| Material | Type of Bioink | Bioprinting Technology | Tissue Engineering Model | Cancer Models | Advantages | Drawbacks | Type of Crosslinking | References | |
|---|---|---|---|---|---|---|---|---|---|
| Bioink derived from natural biomaterials | Alginate-based | Natural polysaccharide | Drop-based | Vascular, cartilage, bone, neural tissue, fibroblast, and many more | Drug delivery | Low cost | Poor cell adhesion | Ionic | [ |
| Gelatin-based | Natural protein | Drop-based | Vascular, cartilage, bone, muscle, fibroblast, and many more | Cholangiocarcinoma, bladder cancer, and many more cancers | Excellent bio-compatibility | Low viscosity at room or higher temperatures | Chemical | [ | |
| Cellulose and nanocellulose-based | Natural polysaccharide obtained from the biosynthesis of plants or bacteria | Filament-based | Cartilage and bone | Drug delivery | Great similarity with ECM | Low viscosity for cellulose nanocrystals | Enzymatic | [ | |
| Matrigel | Solubilized basement membrane matrix secreted by Engelbreth-Holm-Swarm (EHS) mouse sarcoma cells | Filament-based | Vascular, liver, bone, lung, and many more | Tumor spheroids | Most used material in cancer research | Cannot be used alone due to its | Thermal | [ | |
| Collagen-I-based | Natural protein (rat tail or bovine skin and tendon) | Drop-based | Hard tissues (bone, osteochondral, cartilage) | Tumor spheroids | Excellent bio-compatibility | Low shape fidelity | pH | [ | |
| Hyaluronic-acid-based | Natural polysaccharide (bacterial fermentation or animal products) | Filament-based | Hard tissues (bone, osteochondral, cartilage) | Tumor spheroids | Excellent bio-compatibility | Poor mechanical strength | Depends on the other biomaterial/chemical modifications | [ | |
| Agarose-based | Natural polysaccharide derived from red seaweed | Filament-based | Bone, vascular, neural, and adipose tissue | Leukemia | Good biocompatibility | Poor cell survival if not blended with another biomaterial | Thermal | [ | |
| Fibrin-based | Natural protein | Filament-based | Muscular, neural, skin, and adipose tissue, wound healing model | Drug release | High shape fidelity (depending on fibrinogen–thrombin concentration) | Medium cell adhesion | Enzymatic (fibrinogen–thrombin) |
[ | |
| Silk-derived | Natural protein | Filament-based | Hard tissues (bone, osteochondral, cartilage), vascular tissue | Drug delivery | High shape fidelity | Lacks cell-binding domains | Enzymatic |
[ | |
| Gellan gum | Natural polysaccharide | Filament-based | Hard tissues (bone, osteochondral, cartilage), brain-like structures | Drug delivery | Excellent biocompatibility | Poor printability performance | Thermal |
[ | |
| Chitosan | Natural polysaccharide produced by deacetylation of chitin (extract from shrimps) | Filament-based | Hard tissues (bone, osteochondral, cartilage), vascular, skin, and hepatic tissues | Drug delivery | Good biocompatibility | Medium cell adhesion | Ionic |
[ | |
| Polypeptides | Corning (PuraMatrix) | Filament-based | Liver, neural | Ovarian cancer | Self-assembly | Low pH leading to low cell viability | Ionic-complementary self-assembly | [ | |
| De-cellularized matrix-based (dECM) | Natural matrix | Filament-based | Adipose, hepatic, and heart tissues; MSCs; cancer models | Many tumor models depending on dECM | Renders natural ECM | Low mechanical properties | Depends on the other biomaterial/chemical modifications | [ | |
| Bioink derived from synthetic biomaterials | AM (acrylamide) | Polyacrylamide | Filament-based | Different stiffness models | Melanoma, breast cancer | Wide range of elasticity | Suitable for 2D culture only or necessary to couple it with another material | UV | [ |
| PCL/PLGA | Poly(caprolactone)/Poly(lactic–glycolic acid) | Filament-based | Hard tissues (bone, osteochondral, cartilage) | Mainly depends on the natural biomaterial used | Good mechanical strength | Mainly used as a scaffold (melting temperature around 60 °C not compatible with cell viability) | Depends on the natural biomaterial used | [ | |
| PEG | Polymer of ethylene oxide | Filament-based | Vascular and bone tissue | Highly tunable (mechanical properties, polymerization, chemical composition) | Needs chemical modification to be printed | UV if mixed with a photoinitiator | [ | ||
| Pluronic | Triblock copolymer of poly(ethylene glycol)-poly(propylene oxide)-poly(propylene glycol) | Filament-based | Cartilage | High shape fidelity | Lacks cell-binding domains | Covalent | [ | ||
| PU | Polyurethane | Filament-based | Cartilage | Good biocompatibility and biodegradability | Needs other supportive material for cell proliferation (alginate, gelatin, etc.) | Depends on the natural biomaterial used |
[ |
Figure 2Flow chart proposal for the implementation of 3D filament-based bioprinting. Blue—key technical steps; red—influence of technical choices on cell status.
Characterization technology of bioprinted constructs. Value of 3D bioprinting for cancer modelling. + for pros and − for cons.
| Methods | Description | Pros and Cons | Markers | REF | |
|---|---|---|---|---|---|
| Microscopy | |||||
| Light | Phase contrast | Monitoring of proliferation and morphology of cells | +: • Nondestructive | Not suitable | [ |
| Bright field | The transmission of light is more or less attenuated depending on the density or marking of the sample | +: • Suitable for large samples | Hematoxylin–eosin | [ | |
| Fluorescence | LSM | The use of a fluorescent marker is necessary to highlight a subcellular structure; possibility of monitoring structures over time (if vital markers) | +: • Monitoring of many possible structures | Live/dead staining | [ |
| Electronic | Scanning | Surface is scanned with a beam of electrons, emitted signal provides images | +: • High resolution | Not suitable | [ |
| Transmission | The part of beam of electrons is transmitted into specimens allowed to obtain images | Not suitable | [ | ||
| Flow cytometry | |||||
| Flow cytometry | Analysis of physical parameters (size and granularity) for each cell but also the level of fluorescence | +: • Quantitative analysis | 7-AAD | [ | |
| Spectroscopy | |||||
| Spectrometry or fluorimetry | Production or utilization of a fluorescent or chromatic compound | +: • Well-described for 2D culture and frequently used | ACP, LDH, prestoblue, alamar blue, DNA content | [ | |
| Molecular biology | |||||
| RTqPCR | Quantification of gene expression at mRNA or protein level | +: • Quantitative analysis | Bax/Bcl2 | [ | |
| Metabolism | |||||
| GC–MS (Gas chromatography–mass spectrometry) | Detection of molecules of interest according to their mass/charge ratio after ionization | +: • Considerably less cellular material compared to NMR, high sensitivity, | 13C-Glucose | [ | |
| NMR (nuclear magnetic resonance) spectroscopy | Determination of the composition of a sample by applying a magnetic field via the orientation of the nuclear spins of the atoms | +: • High reproducibility, sample can be analyzed directly, low cost | [ | ||
| PET scan (positron emission tomography) | Injection of a radiographic tracer and monitoring by imaging to detect localization of [18F]FDG | +: • Classically used in medicine, monitoring over time | [18F]FDG | [ | |
| Seahorse | Quantification of the oxygen consumption rate (OCR) and the extracellular acidification rate (ECAR) | +: • High sensitivity (from 5000 cells, theoretically), possibility to test many conditions in parallel | Not suitable | [ | |
7-AAD: 7-ADDminoactinomycin; [18F]-FDG: 18F-2-Fluor-2-deoxy-D-glucose; ACP: acid phosphatase assay; CFSE: carboxyfluorescein succinimidyl ester; CTV: celltraceviolet; MTS: 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium; MTT: 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide; pNPP: p-nitrophenyl phosphate; PET: positron emission tomography; WST: water-soluble tetrazolium; XTT: 2,3-bis-(2-methoxy-4-nitro-5-sulfophenyl)-2H-tetrazolium-5-carboxanilide.
Figure 3Examples of possible analysis of 3D bioprinted constructs.
Figure 4Relevance and ease of implementation of different research models.
Figure 5The value of bioprinting for oncology research.
Figure 6Cancer stem cell (CSC) and microenvironment. (A) A tumor is composed of heterogeneous cells, including a small fraction of cancer stem cells (in yellow). These cells are distinguished by their low cycling and their ability to self-renew and differentiate. When the tumor is exposed to treatments or a hypoxic or low-nutrient environment, these cells will resist and survive in a niche that is adapted to them. (B) A large number of CSCs is of interest to test an effective personalized treatment for each patient. For this purpose, a tumor sample must be dissociated by enzymatic and/or mechanical treatment and then cultured in a 3D environment to promote the formation of spheroids in the hydrogel. These cells then show the capacity of tumorigenicity (tumor formation in vivo); overexpression of stemness markers, such as Oct4 and Sox2; and, finally, the capacity to differentiate.
Figure 7Main mechanotransduction pathways. In the green, the influence of mechanotransduction in glucose metabolism; in blue, the influence in amino acid metabolism; in yellow, the influence in lipid metabolism. GSK3: glycogen synthase kinase-3, GLUT: glucose transporter, LDLr: low-density lipoprotein receptor, TXNIP: Thioredoxin interacting protein, ROCK: Rho-associated protein kinase, LPL: lipoprotein lipase, PI3K: Phosphoinositide 3-kinase, FAK: focal adhesion kinase, YAP: Yes-associated protein, AMPK: AMP-activated protein kinase, SREBP: Sterol regulatory element-binding proteins, CD36: cluster of differentiation 36, also known as platelet glycoprotein 4, fatty acid translocase (FAT).